Categories
News

unite.AI_July_20

Avishay Bransky, Ph.D., CEO and Co-founder of PixCell – Interview Series, by Antoine Tardif

Categories
News

medical_plastics_news_July20

FDA clears diagnostic device using flow and imaging cytometry

Categories
Evidence

The HemoScreen in the Operating Room Uppsala University Hospital, Sweden

Categories
Evidence

HemoScreen Vs. Siemens Advia 2120i, Performance and Usability Evaluation at Unilabs

Categories
Testimonials

Prof. Lennart Friis-Hansen

“The CBC analysis performed by large hematology instruments in a centralized laboratory is a screening test. However, despite extensive automation, the centralized laboratories have some inherent challenges (e.g. sample logistics, waiting time on the automated track etc) that makes it difficult to achieve turn-around times (TATs) from requisition/arrival of the patient at the ward to final result in less than 1-2 hrs. A way of overcoming these challenges and achieving TAT < 10 min is to decentralize the CBC analyses using Point-of-care (POC) hematology devices to screen WBC, platelet counts and hemoglobin. These POC instruments could also be excellent candidates for home monitoring of patients obviating the need to travel over long distances to the hospital as they are safe, user-friendly and portable. The HemoScreen instrument provides CBC test with a quality that both fulfil the clinical needs and have a short turnaround time. The robust analytical method with single use cartridge and easy operation makes the HemoScreen a good choice for smaller outpatient clinics and also potentially well suited for home monitoring.
The HemoScreen gives opportunities for use, both in decision-making in relation to general out-patient chemotherapy administration, but also in the out-patient handling of leukemia patients with chemotherapy-induced pancytopenia. Within a few minutes after blood sampling, important decisions can be taken regarding the need for platelet and red blood cell transfusion, but also when to initiate and stop antibiotic prophylaxis depending on the ANC. Out-patients with acute leukemia have numerous visits to the clinic during their treatment, which includes several courses of chemotherapy, leading to deep and prolonged pancytopenia over a total period of 4 to 6 months. The use of HemoScreen in this setting will therefore have considerably impact in reducing the total time spend in hospital on a day to day basis for patients undergoing treatment for acute leukemia. Furthermore, fast decision making in smaller (isolated) units have become very important during the COVID19 epidemic”